nature portfolio | reporting summary

1arch 2021

nature portfolio

Reporting	Summarv

Corresponding author(s):	
Last updated by author(s):	

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

Statistics

Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
☐ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above. Software and code
Policy information about availability of computer code
Data collection
Data analysis For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and
reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information. DataPolicy information about availability of data
Data-officy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: - Accession codes, unique identifiers, or web links for publicly available datasets - A description of any restrictions on data availability - For clinical datasets or third party data, please ensure that the statement adheres to our policy

Policy information about studies involving human research participants and Sex and Gender	
Reporting on sex and gender	nature por!folio
Population Population	-
characteristics	po
Recruitment	
Ethics oversight	<u> </u>
Note that full information on the approval of the study protocol must also be provided in the manuscript.	
Field-specific reporting	reporting summary
rieid-specific lepotcing	pon
	inc
	JS (
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.	Ē
Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences	ma
	Ž
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf	
Life sciences study design	
All studies must disclose on these points even when the disclosure is negative.	
Sample size	
Data exclusions	
Replication Replication	
Randomization	
Blinding	_
Behavioural & social sciences study design	
Denavioural a Boerar Berenceb bear, debign	
All studies must disclose on these points even when the disclosure is negative.	
Study description	
Research sample	
Sampling strategy	
Data collection	
Timing	
Data exclusions	
Non-participation	
Randomization	
Ecological, evolutionary & environmental sciences study design	
All studies must disclose on these points even when the disclosure is negative.	
Study description	
Research sample	
Sampling strategy	
Data collection	
Timing and spatial scale	
Data exclusions	
Reproducibility	
Randomization	Marc
Blinding	March 2021
	021
Did the study involve field work? Yes No	

We require information from authors about some types of materials, experimental systems and methods used in many stuc system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate to the system of	
Mothoda	nature portfolio
Materials & experimental systems Methods _{n/a}	7
n/a Involved in the study	ort
Antibodies ChIP-seq	foli
Eukaryotic cell lines	ō
Palaeontology and archaeology MRI-based neuroimaging	
Animals and other organisms	reporting
Clinical data	<u> </u>
Dual use research of concern	
	ŭ m
Antibodies Antibodies used	summa
Validation	a a
Eukaryotic cell linesPolicy information about cell lines and Sex ar	nd Cender in Research
Cell line source(s)	id Gender in Repearen
Authentication	
Mycoplasma contamination	
Commonly misidentified lines (See ICLAC register)	
Palaeontology and Archaeology	
- 4.24.00.101-101 - 1.11-11-11-1-1-1-1-1-1-1-1-1-1-1-1-1	
Specimen provenance	
Specimen deposition	
Dating methods	
Tick this box to confirm that the raw and calibrated dates are available in the paper or in Suppler	mentary Information.
Ethics oversight	
-	
Note that full information on the approval of the study protocol must also be provided in the manuscript.	
Note that full information on the approval of the study protocol must also be provided in the manuscript. Animals and other research organisms	
	nes recommended for reportation
Animals and other research organisms	nes recommended for reporting
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling	nes recommended for reportains
Animals and other research organisms Policy information about studies involving animals; ARRIVE guidelin Laboratory animals	nes recommended for reportung
Animals and other research organisms Policy information about studies involving animals; ARRIVE guidelin Laboratory animals Wild animals	nes recommended for reporting
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex	nes recommended for report
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples	nes recommended for reporting
Animals and other research organisms Policy information about studies involving animals; ARRIVE guidelin Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight	nes recommended for reporting
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript.	nes recommended for reporting
Animals and other research organisms Policy information about studies involving animals; ARRIVE guidelin Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies	
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT chee	
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT chees submissions.	
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT chee	
Animals and other research organisms Policy information about studies involving animals; ARRIVE guidelin Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checks submissions. Clinical trial registration	
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT check submissions. Clinical trial registration Study protocol	
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT chee submissions. Clinical trial registration Study protocol Data collection	cklist must be included with all
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT chee submissions. Clinical trial registration Study protocol Data collection Outcomes Dual use research of concernPolicy information about dual use research	cklist must be included with all
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT chees submissions. Clinical trial registration Study protocol Data collection Outcomes Dual use research of concernPolicy information about dual use research and use research and use research and use research and use research of concernPolicy information about dual use research and use research of concernPolicy information about dual use research and use research an	cklist must be included with all
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT chee submissions. Clinical trial registration Study protocol Data collection Outcomes Dual use research of concernPolicy information about dual use research in the manuscript, pose a threat to:	arch of concernHazards application of information presented
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT chees submissions. Clinical trial registration Study protocol Data collection Outcomes Dual use research of concernPolicy information about dual use research in the manuscript, pose a threat to: No Yes	arch of concernHazards application of information presented
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT chee submissions. Clinical trial registration Study protocol Data collection Outcomes Dual use research of concernPolicy information about dual use research in the manuscript, pose a threat to:	arch of concernHazards application of information presented
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT chees submissions. Clinical trial registration Study protocol Data collection Outcomes Dual use research of concernPolicy information about dual use research in the manuscript, pose a threat to: No Yes	cklist must be included with all
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT chees submissions. Clinical trial registration Study protocol Data collection Outcomes Dual use research of concernPolicy information about dual use research in the manuscript, pose a threat to: No Yes Public health	arch of concernHazards application of information presented
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT chees submissions. Clinical trial registration Study protocol Data collection Outcomes Dual use research of concernPolicy information about dual use research in the manuscript, pose a threat to: No Yes Public health National security	arch of concernHazards application of information presented
Animals and other research organisms Policy information about studies involving animals; ARRIVE guideling Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. Clinical dataPolicy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT chees submissions. Clinical trial registration Study protocol Data collection Outcomes Dual use research of concernPolicy information about dual use research in the manuscript, pose a threat to: No Yes Public health National security Crops and/or livestock	arch of concernHazards application of information presented

Experiments of concern

Does the work involve any of these experiments of concern:	
No Yes	nature portfolio reporting summary
Demonstrate how to render a vaccine ineffective	ure
Confer resistance to therapeutically useful antibiotics or antiviral agents	pol
Enhance the virulence of a pathogen or render a nonpathogen virulent	rtfo
☐ ☐ Increase transmissibility of a pathogen	<u> </u>
Alter the host range of a pathogen	<u> </u>
Enable evasion of diagnostic/detection modalities	po
Enable the weaponization of a biological agent or toxin	<u> </u>
Any other potentially harmful combination of experiments and agents	s Di
ChIP-seq	m E
Data deposition	ma
Confirm that both raw and final processed data have been deposited in a public database such as GEO. Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks. Data access links May remain private before publication. Files in database submission	Ŋ
Genome browser session	
(e.g. UCSC)	
Methodology Replicates Sequencing depth Antibodies Peak calling parameters Data quality Software Flow Cytometry Plots	
Confirm that: The axis labels state the marker and fluorochrome used (e.g. CD4-FITC). The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical market and plots are contour plots with outliers or pseudocolor plots. A numerical value for number of cells or percentage (with statistics) is provided. Methodology	narkers).
Sample preparation Instrument Software	
Cell population abundance Gating strategy	
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information. Magnetic resonance imaging	
Experimental design Design type Design specifications Behavioral performance measures Acquisition Imaging type(s) Field strength	
Sequence & imaging parameters Area of acquisition	March 2021
Diffusion MRI Used Not used Preprocessing Preprocessing software Normalization Normalization template	37
Noise and artifact removal	1

Volume censoring

Statistical modeling & inference Model type and settings Effect(s) tested
Specify type of analysis: Whole brain ROI-based Both
Statistic type for inference (See Eklund et al. 2016) Correction Models & analysis
n/a Involved in the study
Functional and/or effective connectivity
Graph analysis
Multivariate modeling or predictive analysis
This checklist template is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as

This checklist template is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/bv/4.0/

